Other · developed by OPKO Health
OPK-88006 is a drug given by subcutaneous injection and studied in metabolic dysfunction-associated steatohepatitis (MASH).
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07512427 | Phase 1/2 | MASH | Recruiting | OPK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
MASH
Updated Oct 25, 2026. Something wrong or missing? Report it on the OPK page.
See OPK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OPK catalysts and pipeline →